Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coquelusedal is a herbal medicinal product developed by Laboratoire des Réalisations Thérapeutiques ELERTE, primarily used as an adjunctive treatment for mild acute bronchial disorders. Formulated as a rectal suppository, it is available in specific dosages tailored for infants, children, and adults. The active components consist of soft hydroalcoholic extracts of *Grindelia robusta* and *Gelsemium sempervirens*. *Grindelia* is traditionally utilized for its antitussive and expectorant properties, helping to clear respiratory passages, while *Gelsemium* provides a mild sedative effect to alleviate the irritation and discomfort associated with persistent coughing. It is a well-established therapy in the French pharmaceutical market for managing symptoms of respiratory and ear, nose, and throat (ENT) related conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coquelusedal.